Dual Inhibition of SRC Family Kinases and Sorafenib Enhances Anti-Tumor Activity in Hepatocellular Carcinoma Cells.

in HCC nodules—was noticed in patients with poorer prognosis after 24 months, both in terms of recurrence and overall survival, although the differences did not reach statistical significance ( Figure 1 C).

also in 111,027 other papers